Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CLDX – Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.
CLDX
$32.59
Name : Celldex Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,557,112,320.00
EPSttm : -3.9
finviz dynamic chart for CLDX
Celldex Therapeutics, Inc.
$32.59
1.09%
$0.35
CLDX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

14.04

Margin Of Safety %

Put/Call OI Ratio

1.04

EPS Next Q Diff

0.02

EPS Last/This Y

-0.83

EPS This/Next Y

-0.03

Price

32.58

Target Price

54.33

Analyst Recom

1.38

Performance Q

19.03

Upside

-255.6%

Beta

1.03

Ticker: CLDX




17 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-17CLDX29.640.880.003285
2026-03-18CLDX28.550.891.563284
2026-03-19CLDX30.030.900.293343
2026-03-20CLDX30.90.900.783345
2026-03-23CLDX31.81.150.072877
2026-03-24CLDX31.21.150.322882
2026-03-25CLDX31.681.130.592904
2026-03-26CLDX31.741.121.002955
2026-03-27CLDX30.281.1314.112965
2026-03-30CLDX29.481.210.173096
2026-03-31CLDX31.731.200.073119
2026-04-01CLDX31.281.090.003291
2026-04-02CLDX31.051.092.093291
2026-04-06CLDX31.351.220.243760
2026-04-08CLDX32.411.191.113870
2026-04-09CLDX33.611.190.003896
2026-04-13CLDX32.571.040.814227
DateSymbolLatestP/C OIP/C VolTotal OI
17 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-17CLDX29.64-39.4-47.8-4.77
2026-03-18CLDX28.56-39.4-39.4-4.77
2026-03-19CLDX30.06-39.4-116.2-4.77
2026-03-20CLDX30.90-39.4-103.9-4.77
2026-03-23CLDX31.80-39.4-103.8-4.77
2026-03-24CLDX31.20-39.4-79.7-4.77
2026-03-25CLDX31.66-39.4-96.7-4.77
2026-03-26CLDX31.75-39.4-90.3-4.77
2026-03-27CLDX30.29-39.4-66.4-4.77
2026-03-30CLDX29.48-39.4-76.1-4.77
2026-03-31CLDX31.70-39.4-128.1-4.77
2026-04-01CLDX31.25-39.4-82.4-4.77
2026-04-02CLDX31.05-39.4-85.8-4.77
2026-04-06CLDX31.38-39.4-94.7-4.77
2026-04-07CLDX31.36-39.4-89.2-4.77
2026-04-08CLDX32.42-39.4-105.5-4.77
2026-04-09CLDX33.60-39.4-106.4-4.77
2026-04-10CLDX32.26-39.4-70.4-4.77
2026-04-13CLDX32.58-39.8-94.3-4.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-17CLDX-2.734.4713.93
2026-03-18CLDX-2.734.4713.93
2026-03-19CLDX-2.734.4713.93
2026-03-20CLDX-2.734.4713.93
2026-03-23CLDX-2.734.4713.93
2026-03-24CLDX-2.734.4713.93
2026-03-25CLDX-2.734.4714.29
2026-03-26CLDX-2.734.4714.29
2026-03-27CLDX-2.734.4714.29
2026-03-30CLDX-2.734.4814.29
2026-03-31CLDX-2.734.4814.29
2026-04-01CLDX-2.734.4814.29
2026-04-02CLDX-2.734.4814.29
2026-04-06CLDX-2.733.8514.29
2026-04-07CLDX-2.733.8514.29
2026-04-08CLDX-2.733.8514.29
2026-04-09CLDX-2.733.8514.29
2026-04-10CLDX-2.733.8514.29
2026-04-13CLDX-2.373.8614.04
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-1.22

Avg. EPS Est. Current Quarter

-1.13

Avg. EPS Est. Next Quarter

-1.2

Insider Transactions

-2.37

Institutional Transactions

3.86

Beta

1.03

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

21

Growth Score

30

Sentiment Score

97

Actual DrawDown %

43

Max Drawdown 5-Year %

-73.1

Target Price

54.33

P/E

Forward P/E

PEG

P/S

1617.12

P/B

4.11

P/Free Cash Flow

EPS

-3.9

Average EPS Est. Cur. Y​

-4.73

EPS Next Y. (Est.)

-4.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-16737.19

Relative Volume

0.69

Return on Equity vs Sector %

-76.4

Return on Equity vs Industry %

-59.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

-94.3
CLDX Healthcare
$32.59
📉
Swing / Pullback
Buy the dip on strong trends
30 /100
WEAK
Trend
0/20
Pullback
8/25
Volume
9/15
Valuation
8/20
TP/AR
2/10
Options
3/10
RSI
59.2
Range 1M
70.8%
Sup Dist
2.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
19 /100
WEAK
Momentum
6/25
Growth
5/30
Estimates
0/20
Inst/Vol
7/15
Options
1/10
EPS Yr
-22.7%
EPS NY
0.6%
52W%
89.2%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +66.7% upside
Quality
2/30
Valuation
12/30
Growth
1/25
Stability
9/10
LT Trend
2/5
Upside
+66.7%
Quality
21
Celldex Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 198
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
CLDX

Latest News

Caricamento notizie per CLDX
stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today
news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance
stock history CLDX – Celldex Therapeutics, Inc. invest stock market
stock prices CLDX premarket after hours
ticker CLDX fair value insiders trading